<div id="readability-page-1"><div id="parent_top_div"><p>Zydus Lifesciences on Saturday said its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its drug Desidustat tablets used for treating renal anaemia.</p> <p>  The company has licensed its Desidustat tablets to a subsidiary of China Medical System Holdings Ltd.</p> <p>  CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS, had obtained an exclusive license for the drug from Zydus in 2020.</p> <p>  Desidustat tablets are administered orally for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure.</p> <p>  &#34;We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally,&#34; Zydus Lifesciences MD Sharvil P Patel said in a statement.</p> <p>  The company is happy to partner with CMS and is confident that this will expand access to patients suffering from Chronic Kidney Disease across Greater China, he added.</p> <p>  Desidustat is discovered, developed and marketed by Zydus in India under the brand name Oxemia. More than 1 lakh CKD patients in India have been successfully treated with Oxemia since its launch in 2022, the drug firm stated.</p> <p>There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China.</p></div></div>

<p>Zydus Lifesciences 已獲得中國國家藥品監督管理局對其藥物 Desidustat 的批准，該藥物用於治療慢性腎病（CKD）患者的腎性貧血。該藥物已授權給中國醫療系統控股的子公司 CMS International Development and Management Ltd。Zydus 旨在改善患者的治療效果，並擴大在大中華區的 CKD 治療覆蓋面，該地區有超過 1.2 億 CKD 患者。Desidustat 在印度以 Oxemia 的品牌銷售，自 2022 年上市以來，已有超過 100,000 名患者接受治療</p>

Zydus 的藥物 Desidustat 用於治療腎性貧血已獲得中國監管機構的批准